Signal
CJC-1295 + IPA (Without DAC) 5 mg
Research Use Only
CJC-1295 without DAC blended with ipamorelin, supplied as a reference peptide for GHRH and ghrelin-receptor signalling research.
Price on Request
In stockInternal Batch
Pending publication
Category
Signal
Certificate of Analysis
Third-party testing in progress
The Certificate of Analysis will be published upon completion.
What Is This Compound?
A research blend of CJC-1295 without DAC (also known as modified GRF 1-29, a growth hormone-releasing hormone analogue) and ipamorelin, a selective growth hormone secretagogue receptor peptide.
Scientific Overview
The two components are studied together because they act on distinct receptors: the GHRH receptor and the ghrelin/GHS receptor. Laboratory research examines receptor binding, signalling kinetics, and combined pathway behaviour.
Scientific Classification
Research blend: GHRH analogue + GHS-receptor peptide
Primary Research Areas
- GHRH receptor signalling
- GHS-R1a (ghrelin receptor) signalling
- Pituitary somatotroph biology
- Combined receptor-pathway research
Biological Pathway or Mechanism
Studied across the hypothalamic-pituitary GHRH axis and the ghrelin receptor pathway in receptor-binding and endocrine-signalling research models.
Research Status
Neither component is an approved medicine. Supplied strictly as a laboratory reference blend; no human-use or outcome claims are made.
Scientific descriptions are provided in English to preserve accurate terminology.
Product Specifications
COA & Batch Documentation
Lot Number:
The Certificate of Analysis will be published upon completion.
This Certificate of Analysis applies only to the tested sample and the lot identified in the original laboratory document. It must not be interpreted as applying to another product, strength, lot, or batch.
Potential Benefits
The information below is provided for educational and scientific discussion purposes only. It summarizes research areas that have been explored in laboratory, preclinical, or published scientific research. It is not medical advice and must not be interpreted as evidence of safety, effectiveness, or suitability for human use.
- Studied in laboratory research involving GHRH receptor signalling
- Investigated in preclinical research related to pituitary somatotroph signalling
- Explored in published research concerning peptide conjugation and half-life research
- Examined in laboratory models of endocrine signalling kinetics in vitro
FDA Disclaimer
† These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Research Disclaimer — Research Use Only
This information is provided for general scientific and educational purposes. The product is not intended for human consumption, diagnosis, treatment, prescribing, administration, or dosing. References to approved medicines do not mean that this research product is equivalent to an approved pharmaceutical product.
